ClinicalCodes.org

An online clinical codes repository to improve validity and reproducibility of medical database research

Research article:

Examining variations in prescribing safety in UK general practice: a cross-sectional study using the Clinical Practice Research Datalink

Reference:

S Jill Stocks, Evangelos Kontopantelis, Artur Akbarov, Sarah Rodger, Anthony J Avery, Darren M Ashcroft(2015) Examining variations in prescribing safety in UK general practice: a cross-sectional study using the Clinical Practice Research Datalink. BMJ, doi: 10.1136/bmj.h5501

Link to fulltext article
http://www.bmj.com/content/351/bmj.h5501
Abstract
Study question What is the prevalence of different types of potentially hazardous prescribing in general practice in the United Kingdom, and what is the variation between practices? Methods A cross sectional study included all adult patients potentially at risk of a prescribing or monitoring error defined by a combination of diagnoses and prescriptions in 526 general practices contributing to the Clinical Practice Research Datalink (CPRD) up to 1 April 2013. Primary outcomes were the prevalence of potentially hazardous prescriptions of anticoagulants, anti-platelets, NSAIDs, β blockers, glitazones, metformin, digoxin, antipsychotics, combined hormonal contraceptives, and oestrogens and monitoring by blood test less frequently than recommended for patients with repeated prescriptions of angiotensin converting enzyme inhibitors and loop diuretics, amiodarone, methotrexate, lithium, or warfarin. Study answer and limitations 49 927 of 949 552 patients at risk triggered at least one prescribing indicator (5.26%, 95% confidence interval 5.21% to 5.30%) and 21 501 of 182 721 (11.8%, 11.6% to 11.9%) triggered at least one monitoring indicator. The prevalence of different types of potentially hazardous prescribing ranged from almost zero to 10.2%, and for inadequate monitoring ranged from 10.4% to 41.9%. Older patients and those prescribed multiple repeat medications had significantly higher risks of triggering a prescribing indicator whereas younger patients with fewer repeat prescriptions had significantly higher risk of triggering a monitoring indicator. There was high variation between practices for some indicators.Though prescribing safety indicators describe prescribing patterns that can increase the risk of harm to the patient and should generally be avoided, there will always be exceptions where the indicator is clinically justified. Furthermore there is the possibility that some information is not captured by CPRD for some practices—for example, INR results in patients receiving warfarin. What this study adds The high prevalence for certain indicators emphasises existing prescribing risks and the need for their appropriate consideration within primary care, particularly for older patients and those taking multiple medications. The high variation between practices indicates potential for improvement through targeted practice level intervention.
Author for correspondence
Jill Stocks
Email for correspondence
jill.stocks@manchester.ac.uk

Clinical code lists:

Click to view and download

Code list
Res25: P1asthma Download this codelist
Res25: P2_LABAICS Download this codelist
Res25: gastroprotection Download this codelist
Res25: P3_clopidogrel Download this codelist
Res25: P5_heart_failure Download this codelist
Res25: CKD Download this codelist
Res25: warfarin Download this codelist
Res25: P13_dementia Download this codelist
Res25: contraceptives Download this codelist
Res25: P17_BMI Download this codelist
Res25: P18_current_smoker Download this codelist
Res25: P19_HRT_oestrogens Download this codelist
Res25: M1_U&E Download this codelist
Res25: M3_methotrexate Download this codelist
Res25: M4_lithium Download this codelist
Res25: M5_INR Download this codelist
Res25: P5_glitazone Download this codelist
Res25: P1betablockers Download this codelist
Res25: P3_peptic Download this codelist
Res25: P3_P11_aspirin Download this codelist
Res25: NSAID Download this codelist
Res25: P8_metformin Download this codelist
Res25: P9_digoxin Download this codelist
Res25: P13_psychosis Download this codelist
Res25: P16_thrombosis Download this codelist
Res25: P18_smoking_status Download this codelist
Res25: P19_brca Download this codelist
Res25: M1_ACEI_loopdiuretic Download this codelist
Res25: M2_TFT Download this codelist
Res25: M3_LFT_FBC Download this codelist
Res25: M4_Li_level Download this codelist
Res25: M2_amiodarone Download this codelist
Res25: P13_antipsychotics Download this codelist

0 comments have been posted.

Please log in to leave a comment.